glp-1 clinical studies Timeline of discovery and development. (a) Key events in Who is a Good Candidate

Retatrutide is a triple-agonist research peptide studied for its interaction with GIP, GLP-1, and glucagon receptors

The trial validates an oral maintenance strategy following successful injectable-led weight loss, promises to improve patient convenience and adherence through a simple daily pill, and does so with a reassuring safety profile

In addition, although numerous strategies for managing these AEs have been described, their application in clinical practice continues to evolve

Keep Weekly Weight Loss Under About 1% of Bodyweight A 200 lb person should lose no more than 2 lb per week

You've got this

reported LY3298176, a novel dual GIP and GLP-1R agonist for the treatment of type 2 diabetes, a study that demonstrated its potential from discovery to clinical proof-of-concept (Coskun et al., 2018)